* VAXON BIOTECH *
2004 - IDF
Key words: Therapeutic vaccines, Cryptic peptides
Mission: to develop innovative therapeutic vaccines for the treatment of cancer including lung, prostate, breast, renal, liver and colorectal cancer, using proprietary technology of optimized cryptic peptides
Age: 14 year(s)
Personal venture |
Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
Sc.Dir.-CSO: Kosmatopoulos (Kostas) [born 1950, M.D., Ph.D., also Chairman, ex-Inserm]
Financers (Hist.): Génopole 1er Jour (G1J), Inserm-Transfert, privately owned
Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Vaccines
Position : Clinical
Company confirm : none
| 2011 .08 || Research : 2 publication in Cancer Immunology Immunotherapy and in Annals of Oncology presenting immunological and clinical data in cancer patients vaccinated with Vx-001 || R&D || [7 years] |
| 2010 .05 || Clinical trial (phase II) for Vx-001 therapeutic vaccine (end) || CLIN || [6 years] |
| 2010 .02 || Registration : orphan Drug designation by FDA for Vx-001 in the treatment of NSCLC || MKTG || [6 years] |
| 2009 .00 || Nomination : François Vallet, as CEO, replacing Philippe Berthon || ORGN || [4 years] |
| 2007 .11 || Registration : orphan Drug designation by EMEA for Vx-001 in NSCL cancer || MKTG || [3 years] |
| 2006 .00 || Company move from Evry Genopole to Paris || ORGL || [1 year] |
| 2004 .12 || Clinical trial (phase I) for Vx-001 (beginning, proof of principle) || CLIN || [0 year] |
| 2004 .06 || Company founded by Dr Kostas Kosmatopoulos, Inserm, with Philippe Berthon [Ph.D.] nominated as CEO, located at Evry Genopole || ORGF || [0 year] |
Actualisation / Updating: 7-Dec-2012